SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ArriVent ARR-217 Shows 44.8% Response Rate in Phase 1 Trial

ArriVent reported a 44.8% response rate for ARR-217 at 6 mg/kg in a Phase 1 colorectal cancer trial.

AVBP

Related stories